Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.50 - $66.54
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.00M
Market Cap
$574.97M
Enterprise Value$1.16B
Total Cash (Recent Filing)$16.71M
Total Debt (Recent Filing)$12.30M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 07, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding40,490,543
10 Day Avg. Volume1,340,591
30 Day Avg. Volume1,000,656
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.19
Price to Cash Flow (P/CF)-59.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.75
Enterprise Value/Ebitda-48.93
Forecast
1Y Price Target
$27.60Price Target Upside91.27% Upside
Rating ConsensusHold
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityRXST could benefit from a competitor's recall that likely isn't baked into guidance.
Market ValuationThe shares are trading at about 4.1x NTM EV/Sales, below peers at 5.3x NTM EV/Sales, and RXST's estimated CAGR of approximately 26% on a 3-year basis is still ahead of peers at 18%.
Technology And InnovationThere is still a lot to like about the company's story, including its highly differentiated technology and improving margin profile.
Bears Say
Competitive PressureA weakened premium IOL market and sequential launches of competitive premium IOLs have contributed to the company's challenges.
Financial PerformanceRXST preannounced revenue missed consensus by approximately 5%.
Guidance And ForecastingThe company's guidance for the full year has been significantly reduced, with expected revenues now lower than prior forecasts.
---
Ownership Overview
4.86% Insiders
19.04% Mutual Funds
1.71% Other Institutional Investors
59.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $13.50 and its highest was $66.54 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $574.97M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is May 07, 2025 which is in 14 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Feb 25, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.166 by $0.016.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.22.
How many shares outstanding does RxSight have?
RxSight has 40,490,543 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.166. Following the earnings report the stock price went down -0.822%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
---
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$27.60 (91.27% Upside)
$27.60 (91.27% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 845.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.46%
12-Months-Change
Fundamentals
Return on Equity
-12.43%
Trailing 12-Months
Asset Growth
76.07%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
---
RXST Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth, gross margin expansion, and positive adjusted net income. However, the company continues to face net losses and increased operating expenses. The introduction of new product features and FDA approvals positions the company well for future growth.Read More>---
RXST Stock 12 Month Forecast
Average Price Target
$27.60
▲(91.27% Upside)
Technical Analysis
Best Analysts Covering RXST
1 Year
1 Year Success Rate
13/23 ratings generated profit
1 Year Average Return
+50.44%
reiterated a buy rating 15 days ago
Copying David Saxon's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +50.44% per trade.
---